Navigation Links
Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section

BRIDGEWATER, England, September 9 /PRNewswire/ -- Clinical Therapeutics,( the world's premier, rapid-publication journal, is proud to announce the addition of Michael G. Spigarelli, MD, PhD, to our distinguished editorial board.

As section editor for the Pediatric, Adolescent, & Maternal Therapeutics ( section (formerly the Pediatric Research section), Dr. Spigarelli brings a wealth of knowledge and a strong background in addressing the issues surrounding these special populations. He completed his residency in internal medicine and pediatrics at the University of Michigan Medical Center in Ann Arbor and his fellowship in adolescent medicine at Cincinnati Children's Hospital Medical Center, where he currently remains on staff.

Pregnant women and children remain among the most vulnerable patients undergoing therapy today due to a lack of critical information on the safety, tolerability, and efficacy of pharmacotherapies indicated for them. As Dr. Spigarelli states in his inaugural editorial, "To date, most medications used in the treatment of illness in children have never been tested in them.... This lack of crucial information has important implications for a variety of stakeholders."

By refocusing the Pediatric, Adolescent, & Maternal Therapeutics ( section, Clinical Therapeutics( seeks to become the premier venue for publication of clinical research in these special populations and serve as an international forum for the timely discussion of safe and effective drug therapies in neonates, infants, children, adolescents, and pregnant or lactating women.

"As Editor of this section, I encourage each of you to review your files for data already obtained but not yet published, for data from ongoing studies, and consider submitting those manuscripts to Clinical Therapeutics. Each additional piece of available data adds to the knowledge base needed to provide the best health care for pregnant women and children."

An example of important pediatric information published by the journal is the supplemental issue on Conquering Pain: The Hidden Cost of Immunization sponsored by the Canadian Institutes of Health Research and the SickKids Foundation. Also highlighting the journal's commitment to fostering publication of scientific research related to these special populations is the upcoming focus issue on vaccines.

Articles can be submitted online or directly to; click here for Information for Authors (

For more information about this press release and Clinical Therapeutics, contact Julie E. Artim at:

    Phone: +44(0)908-547-2094

SOURCE Clinical Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Akaza Research to Present OpenClinica 3.0 at Upcoming Clinical Research Conferences: SoCRA, SCDM
2. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
3. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
4. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
5. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
6. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
7. Clinical Trials Offices Changing Academic Health Center Research Infrastructure
8. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
9. goBalto Drug Development Partnering WebSite to Include Clinical Trials Support's List of Investigator Sites
10. Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study
11. Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona(TM) ) in Mild to Moderate Alzheimers Disease
Post Your Comments:
(Date:10/13/2015)... Oct. 13, 2015  According to Kalorama Information, ... reach $102 billion by the end of 2015. ... health industry, as it is estimated that approximately ... laboratory tests. In addition to diagnosing patients, clinical ... disease progression, monitor drug treatment and conditions, and ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... distributor of automation systems, material handling solutions and components, is opening its latest ... near State Street, the facility is Exotic’s second major expansion in Metropolitan Detroit ...
(Date:10/13/2015)... Charlotte, NC (PRWEB) , ... October 13, 2015 ... ... high intensity focused ultrasound (HIFU) technologies, announced today that it received de novo ... 450 in the U.S. for the ablation of prostate tissue. Sonablate® is ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... educational opportunities for school age children in the areas of Science, Technology, Engineering ... sectors of the national economy, and the program aims to increase the number ...
Breaking Biology Technology:
(Date:10/12/2015)... 2015 NXTD ) ("NXT-ID" or the ... commerce market, reports on the recent SNS Future in Review ... --> NXTD ) ("NXT-ID" or the "Company"), a biometric ... on the recent SNS Future in Review Conference in ... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/8/2015)... 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet announces that revenues for the three months ... with $113,00 for the three months ended June ... September 30, 2015 were approximately $520,000. ...
(Date:10/5/2015)... ) releases the following ... NXTD ), a biometric authentication company focused on the ... ) releases the following market and company update ... authentication company focused on the growing mobile commerce market. ... ) releases the following market and company update ...
Breaking Biology News(10 mins):